Proactive Investors - Run By Investors For Investors

Ventripoint showcases its latest VMS+3.0 cardio-monitoring system at American College of Cardiology's 68th Annual conference

VMS+3.0 is Ventripoint's newest version of its machine, which revolutionizes the way doctors treat heart patients as it gives accurate and rapid volumetric information on all four chambers of the heart
heart in hand
The Toronto company seized the opportunity to showcase the latest advances in its technology at the ACC’s Annual Scientific Session & Expo

Ventripoint Diagnostics Ltd (CVE:VPT) (OTCQB:VPTDF) said Tuesday that it staged a successful hands-on demonstration of its next-generation VMS+3.0 system at the American College of Cardiology’s 68th Annual Scientific Session & Expo in New Orleans over the weekend (March 16-March 18).

Not yet available for sale, the VMS+3.0 system is Ventripoint’s latest version of its machine, which revolutionizes the way doctors treat heart patients as it can give accurate and rapid volumetric information about all four chambers of the heart.

READ: VentriPoint Diagnostics' heart monitoring tech further boosted by agreement with Canadian government

It is the only technology in the world that can perform such an analysis of all four chambers using data from a conventional 2D (two dimensional) eco-cardiogram (in other words an ultrasound test).

Ventripoint's most up-to-date 3.0 system uses sensor technology, which allows for patients to move during the imaging portion of the examination, and it is compact and portable enough that it can be set up within minutes.

The Toronto company seized the opportunity to showcase the latest advances in its technology at the ACC’s Annual Scientific Session & Expo, which was attended by nearly 20,000 cardiologists.

The VMS+3.0 system is for investigational use only.

READ: Ventripoint Diagnostics reports progress for latest VMS +3.0 heart monitoring system

Ventripoint has developed a suite of applications to monitor heart disease. Its VMS+ system is the first AI tool for measuring the function of the entire heart using ultrasound.

Ventripoint shares closed at C$0.175 in Canadian trade on Monday.

Contact Ellen Kelleher at [email protected]

View full VPT profile View Profile

VentriPoint Diagnostics Ltd. Timeline

Related Articles

Social media use
April 18 2019
Social first has allowed sites like UNILAD to amass a huge audience with very little capital injection, but what is social first publishing and how is it changing the nature of content and advertising?
An instrument made by Pressure BioSciences
June 26 2019
The company’s high-pressure technologies can help drug makers produce protein-based therapeutics, a market expected to touch $240 billion by 2023
Pictured is the company's myLotus test
May 15 2019
Here we take a closer look at testing firm Concepta PLC (LON:CPT)
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use